drugset / Trial / NCT05817422

Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults

NCT05817422 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults

Timeline

Start
2023-10-19
Primary completion
2025-04-25
Completion
2025-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject cAd3-Marburg Vaccine 1e+11 unknown Intramuscular